Home › All Companies › TXG

10x Genomics, Inc. (TXG)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-03-25

Key Insights

  • The CEO Serge Saxonov sold a total of 15,000 shares of 10x Genomics Class A common stock on March 23 and March 24, 2026, indicating some insider selling activity.
  • Saxonov holds a significant beneficial ownership stake in 10x Genomics, including direct ownership of over 1.1 million Class A shares and indirect ownership through various trusts and irrevocable trusts.
  • The filing discloses details on Saxonov's Class B common stock holdings, which are convertible to Class A shares and represent significant voting power.
Sentiment: Neutral Significance: 6/10
View Original Filing →
Annual Report Filed: 2026-02-13

Key Insights

  • 10x Genomics reported strong revenue growth of 25% year-over-year in 2025, driven by continued demand for its product and service offerings.
  • The company's gross margin improved by 2 percentage points in 2025, indicating improved operational efficiency and cost control.
  • 10x Genomics provided a positive outlook for 2026, forecasting 18-22% revenue growth and stable profitability, though the acquisition of Scale BioScience introduces some uncertainty.
Sentiment: Positive Significance: 7/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.